Xilonix, a Novel True Human Antibody Targeting the Inflammatory Cytokine Interleukin-1 alpha, in Non-Small Cell Lung Cancer

BACKGROUND: Advanced non-small cell lung cancer (NSCLC) patients were treated as part of a Phase I dose escalation and expansion study evaluating a true human monoclonal antibody targeting IL-1α (Xilonix), which is intended to modulate the malignant phenotype—inhibiting tumor growth, spread and offe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Hong, David S., Janku, Filip, Naing, Aung, Falchook, Gerald S., Piha-Paul, Sarina, Wheler, Jennifer J., Fu, Siqing, Tsimberidou, Apostolia M., Stecher, Michael, Mohanty, Prasant, Simard, John, Kurzrock, Razelle
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482235/
https://ncbi.nlm.nih.gov/pubmed/25822109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0226-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars